In particular, poziotinib has shown superior activity against NSCLC patients with HER2 exon 20 mutations in ex vivo experiments and several phase II clinical trials (ORR 39%, DCR 73%) [129]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.